Importantly, since GATA2 functions upstream of NR3C1 and other enzalutamide-induced cancer-promoting genes (e.g. SLC7A11 and LAMP3) (Figures 2–4, Supplementary Figures S10, S13–S15), targeting GATA2 maybe a better strategy for improving AR-targeted therapy by enzalutamide (Supplementary Figure S17). The gene discussed is NR3C1; the disease is cancer.